Drugs that will be subject to rebates in 340B next year include Bristol Myers Squibb’s Eliquis, Johnson & Johnson’s Stelara ...

The American Society of Health-System Pharmacists is urging lawmakers to protect the 340B Drug Pricing Program, warning that changes to the discount model could destabilize safety-net hospitals. In an ...

Lawmakers called for more transparency about how hospitals are using 340B revenue, including audits of participating ...

The Health Resources and Services Administration posted on its website that it had approved eight drug company plans for participation in the 340B Rebate Model Pilot Program with a start date of Jan.

Impact: Immediate Savings to Requesting Rebates WATKINSVILLE, GA / ACCESS Newswire / October 28, 2025 / Rural hospitals in the 340B program are about to feel a new financial pressure. On January 1, ...

Lawmakers impatient with the lack of progress on a key health care issue — the long-debated need for changes to what’s known ...

This approach would aim to raise the same amount of revenue that was previously generated by covered entities’ arbitrage of ...

Even as they sparred on broader healthcare policy and funding topics fueling the ongoing government shutdown, senators of the ...

AHA writes to express our strong support for this vital program that allows eligible hospitals to maintain, improve and expand access to essential services and medications for the patients and ...

FAH rebuts Senate hearing claims, clarifying taxpaying hospitals do not benefit from the 340B drug pricing program discounts.

In a decision likely to send shockwaves through the 340B Program space, the United States District Court of South Carolina recently provided a favorable ruling to 340B-participating covered entities ...

On November 3, a federal district court issued a monumental decision endorsing an expansive view of who is a “patient” of a 340B program covered entity eligible to receive a 340B drug. In Genesis ...